Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optimoz Plus is a combination nutraceutical and pharmaceutical supplement developed by Jay Ell Healthcare for the management of Polycystic Ovary Syndrome (PCOS) and associated metabolic complications. It features a synergistic formulation of **metformin** (500mg), an insulin-sensitizing biguanide, alongside **myo-inositol** (550mg) and **d-chiro inositol** (13.8mg) in a physiologically relevant 40:1 ratio. The product also includes **L-methylfolate calcium** (0.5mg) and **vitamin B12** (750mcg) to support homocysteine metabolism and address potential nutritional deficiencies. Optimoz Plus is designed to target hyperinsulinemia, restore hormonal balance, improve oocyte quality, and regulate menstrual cycles in PCOS patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Optimoz Plus.